Literature DB >> 11774082

Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.

Lorraine Kyne1, Mary Beth Hamel, Rajashekhar Polavaram, Ciarán P Kelly.   

Abstract

A total of 271 patients were prospectively followed up to determine whether patients whose hospital stay is complicated by diarrhea due to Clostridium difficile experience differences in cost and length of stay and survival rates when compared with patients whose stay is not complicated by C. difficile-associated diarrhea. Forty patients (15%) developed nosocomial C. difficile-associated diarrhea. These patients incurred adjusted hospital costs of $3669--that is, 54% (95% confidence interval [CI], 17%-103%)--higher than patients whose course was not complicated by C. difficile-associated diarrhea. The extra length of stay attributable to C. difficile-associated diarrhea was 3.6 days (95% CI, 1.5-6.2). C. difficile-associated diarrhea was not associated with excess 3-month or 1-year mortality after adjustment for age, comorbidity, and disease severity. On the basis of the findings of this study, a conservative estimate of the cost of this disease in the United States exceeds $1.1 billion per year.

Entities:  

Mesh:

Year:  2001        PMID: 11774082     DOI: 10.1086/338260

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  226 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

Review 2.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 3.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

4.  Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency.

Authors:  J H Boone; M Goodykoontz; S J Rhodes; K Price; J Smith; K N Gearhart; R J Carman; T M Kerkering; T D Wilkins; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-14       Impact factor: 3.267

Review 5.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

Review 6.  Clindamycin as an antimalarial drug: review of clinical trials.

Authors:  Bertrand Lell; Peter G Kremsner
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Outcomes of Chronic Pancreatitis in the Emergency Department.

Authors:  Julia McNabb-Baltar; Shadeah L Suleiman; Peter A Banks; Darwin L Conwell
Journal:  Dig Dis Sci       Date:  2018-07-23       Impact factor: 3.199

Review 8.  Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs.

Authors:  Günter Kampf; Axel Kramer
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples.

Authors:  Paul D Stamper; Romina Alcabasa; Deborah Aird; Wisal Babiker; Jennifer Wehrlin; Ijeoma Ikpeama; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

10.  A novel subtyping assay for detection of Clostridium difficile virulence genes.

Authors:  Stephanie L Angione; Aartik A Sarma; Aleksey Novikov; Leah Seward; Jennifer H Fieber; Leonard A Mermel; Anubhav Tripathi
Journal:  J Mol Diagn       Date:  2014-01-13       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.